J
John Stewart
Researcher at University of Hartford
Publications - 31
Citations - 1260
John Stewart is an academic researcher from University of Hartford. The author has contributed to research in topics: Cabazitaxel & Docetaxel. The author has an hindex of 14, co-authored 30 publications receiving 1181 citations. Previous affiliations of John Stewart include Washington State University & Cornell University.
Papers
More filters
Journal ArticleDOI
Productivity Differences Among Scientists: Evidence for Accumulative Advantage
Paul D. Allison,John Stewart +1 more
TL;DR: In this paper, the authors show that the distribution of productivity becomes increasingly unequal as a cohort of scientists ages, and that this increase is highly associated with a changing distribution of time spent on research.
Journal ArticleDOI
Achievement and Ascriptive Processes in the Recognition of Scientific Articles
TL;DR: For example, the authors found that achievement processes are more important than ascriptive processes in the distribution of scientific influence in geoscience articles, and that citations to articles provide a measure of their influence on others.
Journal ArticleDOI
Expression of AR-V7 and ARv 567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.
Scott T. Tagawa,Emmanuel S. Antonarakis,Ada Gjyrezi,Giuseppe Galletti,Seaho Kim,Daniel Worroll,John Stewart,Atef Zaher,Ted P. Szatrowski,Karla V. Ballman,Katsuhiro Kita,Shinsuke Tasaki,Yang Bai,Luigi Portella,Brian Kirby,Fred Saad,Mario A. Eisenberger,David M. Nanus,Paraskevi Giannakakou +18 more
TL;DR: Although detection of both CTC-specific AR-V7 and ARv567es by ddPCR influenced taxane outcomes, AR-v7 primarily mediated the prognostic impact.
Journal ArticleDOI
Interpretive Listening: An Alternative to Empathy.
TL;DR: In this paper, an alternative approach to listening which is grounded in the hermeneutic phenomenologies of Martin Heidegger, Hans-Georg Gadamer, and Paul Ricoeur is presented.
Journal ArticleDOI
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis,Scott T. Tagawa,Giuseppe Galletti,Daniel Worroll,Karla V. Ballman,Marie Vanhuyse,Guru Sonpavde,Scott North,Costantine Albany,Che-Kai Tsao,John Stewart,Atef Zaher,Ted H. Szatrowski,Wei Zhou,Ada Gjyrezi,Shinsuke Tasaki,Luigi Portella,Yang Bai,Timothy B. Lannin,Shalu Suri,Conor N. Gruber,Erica D. Pratt,Brian Kirby,Mario A. Eisenberger,David M. Nanus,Fred Saad,Paraskevi Giannakakou +26 more
TL;DR: The early taxane switch strategy was associated with improved PSA response rates versus TAX327 and taxane-induced shifts in %ARNL may serve as an early biomarker of clinical benefit in patients treated with taxanes.